Shots:
- Trial enrolled 695 MIBC pts undergoing radical cystectomy who were ineligible for or declined cisplatin & randomized them to Arm 1 [neoadj. 3 Imfinzi + EV cycles with Imjudo (2 cycles), then adj. Imfinzi (9 cycles) + 1 Imjudo cycle], Arm 2 [neoadj. Imfinzi + EV (3 cycles), then adj. Imfinzi (9 cycles)], or Arm 3 comparator
- Trial showed Imfinzi + EV showed improvements in EFS & OS. Perioperative Imfinzi + Imjudo in combination with neoadj. EV also showed improved EFS & a favorable OS trend, with OS evaluation to continue in the future
- Also, Imfinzi + BCG therapy met the 1EP of disease-free survival in high-risk non-MIBC pts in the P-III (POTOMAC) trial & is under regulatory review in the US, EU, Japan, & other countries
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News: AstraZeneca Presents the P-III (CALYPSO) Trial Data on Eneboparatide in Chronic Hypoparathyroidism (HypoPT) at ECE’26
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
